Comment
Author: Admin | 2025-04-28
With placebo. Hepatic ImpairmentReduced dosage required in patients with severe hepatic impairment (Child-Pugh score: 7–15). In patients with mild hepatic impairment (Child-Pugh score: 5–6), consider reduced frequency and/or dosage. Use of bupropion hydrochloride extended-release, 450-mg tablets (Forfivo XL) not recommended in patients with hepatic impairment.Renal ImpairmentUse with caution; parent drug and active metabolites may accumulate. Monitor closely for adverse effects that could indicate high bupropion or metabolite exposures; reduction in dosage and/or frequency may be necessary. Use of bupropion hydrochloride extended-release, 450-mg tablets (Forfivo XL) not recommended in patients with renal impairment.Common Adverse EffectsCommon adverse effects (≥5%) in patients receiving conventional bupropion hydrochloride tablets: Agitation, dry mouth, constipation, headache/migraine, nausea/vomiting, dizziness, excessive sweating, tremor, insomnia, blurred vision, tachycardia, confusion, rash, hostility, cardiac arrhythmias, auditory disturbance.Common adverse effects (≥5%) in patients receiving bupropion hydrochloride extended-release, film-coated tablets (e.g., Wellbutrin SR): Headache, dry mouth, nausea, insomnia, dizziness, pharyngitis, constipation, agitation, anxiety, abdominal pain, tinnitus, tremor, palpitation, myalgia, sweating, rash, anorexia.Common adverse effects (≥5%) in patients receiving bupropion hydrochloride extended-release (SR) tablets for smoking cessation: Insomnia, rhinitis, dry mouth, dizziness, nervous disturbance, anxiety, nausea, constipation, arthralgia.Common adverse effects (≥5%) in patients receiving bupropion hydrochloride extended-release tablets (e.g., Wellbutrin XL, Forfivo XL ): Dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash. Common adverse effects (≥5%) in patients receiving bupropion hydrobromide extended-release tablets (e.g., Aplenzin) include dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash.Drug InteractionsMetabolized to hydroxybupropion, principally by CYP2B6; CYP isoenzymes not involved in the formation of other bupropion metabolites. Bupropion and its metabolites inhibit CYP2D6. Drugs Affecting Hepatic Microsomal EnzymesPotential pharmacokinetic interaction (altered serum concentrations of bupropion) with drugs that induce or inhibit CYP2B6. Drugs Metabolized by Hepatic Microsomal EnzymesSubstrates of
Add Comment